Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | F13A1 | P00488 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | TGM1 | P22735 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4550960 | 0.88 | DDB1 (0.40) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL8263573 | 0.82 | ATM (0.38) | F13A1TGM2TGM1ELANEDDB1 | |
| SCHEMBL30077839 | 0.82 | ATM (0.38) | F13A1TGM2TGM1ELANEDDB1 | |
| SCHEMBL28203358 | 0.80 | CHRM2 (0.38) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL28202603 | 0.80 | CHRM2 (0.38) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL24757382 | 0.80 | HSD17B10 (0.40) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL22251831 | 0.80 | HSD17B10 (0.40) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL15606327 | 0.79 | HSD17B10 (0.47) | USP2SMN1; SMN2HSD17B10NR1H2 | |
| Ethylene SCHEMBL5865026 | 0.79 | SETD7 (0.39) | USP2SMN1; SMN2HSD17B10KDM4EMAPT | |
| SCHEMBL4547486 | 0.79 | HSD17B10 (0.47) | USP2SMN1; SMN2HSD17B10NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109843892-B | Oxadiazepinone derivatives and their use in the treatment of hepatitis B infections | 诺维拉治疗公司 | 2022-01-25 | — | — | CN | disclosed |
| US-20210252014-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS INC (US) | 2021-08-19 | — | — | US | disclosed |
| US-10987359-B2 | Oxadiazepinone derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| WO-2020243135-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-03 | — | — | WO | disclosed |
| US-20200197408-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2020-06-25 | — | — | US | disclosed |
| EP-3478692-B1 | OXADIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS INC (US) | 2020-06-17 | — | — | EP | disclosed |
| CN-109843892-A | Dislike diazepine ketone derivatives and its purposes in treatment hepatitis B infection | 诺维拉治疗公司 | 2019-06-04 | — | — | CN | disclosed |
| US-9617244-B2 | Antibacterial quinoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-11 | — | — | US | disclosed |
| US-9617244-B2 | Antibacterial quinoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-11 | — | — | US | disclosed |
| EP-2841426-B1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-28 | — | — | EP | disclosed |
| US-20150051244-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN-CILAG (FR) | 2015-02-19 | — | — | US | disclosed |
| US-20150051244-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN-CILAG (FR) | 2015-02-19 | — | — | US | disclosed |
| WO-2013160431-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-31 | — | — | WO | disclosed |
| US-20090192194-A1 | Cyclic Amine Derivatives, Processes For Their Preparation, And Pharmaceutical Compositions Containing Them | ALVARO GIUSEPPE | 2009-07-30 | — | — | US | disclosed |
| US-20070073061-A1 | Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| EP-1622871-A1 | CYCLIC AMINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004099143-A1 | CYCLIC AMINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987359-B2 | Oxadiazepinone derivatives and methods of treating hepatitis B infections | HCCS, SLC10A1, PYGL | CHRM2 4562/4885CHRM1 4188/4885CHRM3 3776/4885 |
| US-20150051244-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | NQO2, NDUFB5, NDUFB7 | CHRM2 1775/4885CHRM1 1180/4885CHRM3 1617/4885 |
| US-20070073061-A1 | Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them | SLC6A4, OPRL1, HCRTR1 | CHRM2 42/4885CHRM1 16/4885CHRM3 53/4885 |
| US-20090192194-A1 | Cyclic Amine Derivatives, Processes For Their Preparation, And Pharmaceutical Compositions Containing Them | SLC6A4, OPRL1, HCRTR1 | CHRM2 42/4885CHRM1 16/4885CHRM3 53/4885 |
| US-20210252014-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | CHRM2 4484/4885CHRM1 4177/4885CHRM3 3560/4885 |
| US-20200197408-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HCCS, SLC10A1, PYGL | CHRM2 4562/4885CHRM1 4188/4885CHRM3 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.